

Req. - Tax Deletion

Access DB# 131231

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabaha Ozy Examiner #: 74141 Date: 8/29/01
Phone: 1616 Phone Number 30 206 22 Serial Number: 10/036819
Building and Bldg. Room Location: 4670 Room 4A45 Results Format Preferred (circle) PAPER DISK E-MAIL
More than one search is submitted, please prioritize searches in order of need.

Provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched.
Indicate selected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or
of the invention. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc, if
Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Use of Biologically active Vrt D
Inventor (please provide full names): HAYES, COLLEEN E. et al.

Original Filing Date: HA Continuation of 07/467,985
12/21/97
See only Searches Only* Please include all pertinent information (patent, child, divisional, or issued patent numbers) along with the
reference cited here.

A method of treating inflammatory
bowel disease by 1- α hydroxyvitamin D₂
Inflammatory bowel disease is
selected from ulcerative colitis &
Crohn's disease.

Thank you

SEEK USE ONLY

Type of Search	Vendor and cost where applicable
NA Sequence (#) <u>918</u>	STN <u>✓</u>
AA Sequence (#) <u>915</u>	Dialog <u>✓</u>
Structure (#) <u>✓</u>	Questel/Orbit <u>✓</u>
Bibliographic	Dr. Link <u>✓</u>
Litigation	Lexis/Nexis <u>✓</u>
Fulltext	Sequence systems <u>✓</u>
Patent Family	WWW/Internet <u>✓</u>
Other	Other (specify) <u>✓</u>

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:56:00 ON 05 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2004 HIGHEST RN 739335-06-9
DICTIONARY FILE UPDATES: 3 SEP 2004 HIGHEST RN 739335-06-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide can tot 193

L93 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 131918-61-1 REGISTRY
CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,
(1 α ,3 β ,7E,22E) - (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 19-Nor-1,25-dihydroxyvitamin D2
CN Paricalcitol
CN Zemplar
FS STEREOSEARCH
DR 539856-25-2
MF C27 H44 O3
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CA, CANCERLIT,
CAPLUS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS,
IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence);
PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

90 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 90 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:134693

REFERENCE 2: 141:134637

REFERENCE 3: 141:82701

REFERENCE 4: 141:65567

REFERENCE 5: 140:412093

REFERENCE 6: 140:334734

REFERENCE 7: 140:332505

REFERENCE 8: 140:327062

REFERENCE 9: 140:281507

REFERENCE 10: 140:276190

L93 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 54573-75-0 REGISTRY

CN 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,
 (1 α ,3 β ,5Z,7E,22E) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1-Hydroxyergocalciferol

CN 1-Hydroxyvitamin D2

CN 1 α -Hydroxyergocalciferol

CN 1 α -Hydroxyvitamin D2

CN Doxercalciferol

CN Hectorol

CN TSA 840

FS STEREOSEARCH

DR 125285-48-5, 87649-67-0

MF C28 H44 O2

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)


DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation,

nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties);
 RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent);
 USES (Uses)

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

139 REFERENCES IN FILE CA (1907 TO DATE)
 139 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:167976
 REFERENCE 2: 141:65567
 REFERENCE 3: 141:64828
 REFERENCE 4: 140:406808
 REFERENCE 5: 140:332505
 REFERENCE 6: 140:327062
 REFERENCE 7: 140:281507
 REFERENCE 8: 140:276190
 REFERENCE 9: 140:259103
 REFERENCE 10: 140:259102

=> d his

(FILE 'HOME' ENTERED AT 14:08:35 ON 05 SEP 2004)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:08:46 ON 05 SEP 2004
 L1 92 S (1ALPHA OR 1 ALPHA OR 1 A) () (HYDROXYVITAMIN OR HYDROXY VITAMI

FILE 'REGISTRY' ENTERED AT 14:09:21 ON 05 SEP 2004
 L2 1 S 54573-75-0

L3 0 S 54573-75-0/CRN

FILE 'HCAPLUS' ENTERED AT 14:09:44 ON 05 SEP 2004

L4 139 S L2

L5 9 S (1ALPHA OR 1 ALPHA OR 1 A) () (HYDROXYERGOCALCIFEROL OR HYDROXY

L6 26 S DOXERCALCIFEROL OR DOXER CALCIFEROL OR HECTOROL OR TSA840 OR

L7 0 S 9 10 SECOERGOSTA 5 7 10 19 22 TETRAENE 1 3 DIOL

L8 159 S L1,L4,L5,L6
E CROHN/CT

L9 0 S L8 AND CROHN?
E E6+ALL
E ULCERATIVE COLITIS/CT
E E3+ALL

L10 0 S L8 AND E2

L11 1 S L8 AND ?ULCER?

L12 0 S L8 AND ?COLIT?

L13 1 S L8 AND ?COLIC?

L14 32 S L8 AND ?INTESTIN?

L15 1 S L14 AND L11,L13

L16 8 S L8 AND ?COLON? AND L14

L17 0 S L8 AND IBD

L18 0 S L8 AND ?INFLAM?(L)BOWEL?
E INFLAMMATORY BOWEL/CT
E E4+ALL

L19 0 S L8 AND E2

L20 2 S (US20020128241 OR US63548939)/PN OR WO2000-US34913/AP,PRN
E HAYES C/AU

L21 85 S E3,E77-E79
E NASHOLD F/AU

L22 17 S E3-E6

L23 0 S L20 AND L8

L24 1 S L21,L22 AND L8
SEL RN L20

FILE 'REGISTRY' ENTERED AT 14:17:34 ON 05 SEP 2004

L25 22 S E1-E22

L26 1 S L25 AND C28H44O3
E C28H44O2/MF

L27 41 S E3 AND C6/ES AND C5-C6/ES AND 3/NR

L28 12 S L27 AND 5 7 10 19 22 TETRAENE AND 1 3 DIOL

L29 8 S L28 NOT D/ELS

L30 7 S L29 NOT L2

L31 6 S L30 NOT T/ELS
SEL RN

L32 0 S E1-E6/CRN

FILE 'HCAPLUS' ENTERED AT 14:20:59 ON 05 SEP 2004

L33 24 S L31

L34 0 S L33 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?CROHN? OR ?ULCER?(L) (CO

L35 167 S L8,L33
E INTESTINE, DISEASE/CT

L36 6 S E2-E54 AND L35
E E3+ALL

L37 7 S L35 AND E11,E12,E10+NT
E E84+ALL

L38 17 S L35 AND E5,E6,E4+NT

L39 17 S L35 AND (E12+OLD,NT,PFT,RT OR E13+OLD,NT,PFT,RT OR E14+OLD,NT
E E3+ALL

L40 29 S L35 AND (E3+OLD,NT,PFT,RT OR E86+OLD,NT,PFT,RT OR E87+OLD,NT,

L41 29 S L36-L40

L42 18 S L41 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)

L43 12 S L42 NOT ?NEOPLAS?

L44 6 S L43 NOT (HEPATOMA/TI OR OSTEOPOROSIS/CW OR RICKETS/CW)

L45 4 S L44 NOT (LIGAND OR SUPPLEMENT)/TI
L46 6 S L42 NOT L43
L47 5 S L46 AND COLON NOT 3/SC
L48 10 S L24,L45,L47

FILE 'MEDLINE' ENTERED AT 14:30:25 ON 05 SEP 2004
L49 62 S L8 OR L31
E CROHN/CT
E E5+ALL
L50 0 S L49 AND E9+NT
E E9+ALL
L51 0 S L49 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?CROHN? OR ?ULCER?(L)COL

FILE 'EMBASE' ENTERED AT 14:31:26 ON 05 SEP 2004
L52 151 S L8 OR L31
E ERGOCALCIFEROL/CT
E E3+ALL
L53 5089 S E1
L54 5301 S E1/BI
E ERGOCALCIFEROL/CT
E E10+ALL
L55 115 S E9
L56 5432 S L52-L55
L57 16 S L56 AND ?CROHN?
L58 12 S L56 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L)COLIT?)
E CROHN/CT
E E5+ALL
L59 14 S L56 AND E1+NT
E IBD/CT
E INFLAMMATORY BOWEL/CT
E E4+ALL
L60 24 S L56 AND E2+NT
E ULCERATIVE COLITIS/CT
E E3+ALL
L61 6 S L56 AND E1+NT
L62 27 S L57-L61
L63 23 S L62 AND PY<=1999

FILE 'REGISTRY' ENTERED AT 14:38:36 ON 05 SEP 2004
L64 3 S 50-14-6 OR 50809-47-7 OR 8042-78-2

FILE 'EMBASE' ENTERED AT 14:39:14 ON 05 SEP 2004
L65 0 S L52 AND L62

FILE 'MEDLINE' ENTERED AT 14:39:21 ON 05 SEP 2004

FILE 'WPIX' ENTERED AT 14:39:42 ON 05 SEP 2004
L66 45 S L1/BIX OR L5/BIX OR L6/BIX
L67 5 S (19 NOR 1 25 ()) (DIHYDROXYVITAMIN OR DIHYDROXY VITAMIN OR DI H
E 19 NOR 1 25 DIHYDROXYVITAMIN D2/CN
E 19-NOR-1,25-DIHYDROXYVITAMIN D2/CN
L68 1 S E3
E RA3C75/DCN
L69 4 S E3-E7
E DOXERCALCIFEROL/CN
L70 1 S E3
E RA7AA1/DCN
L71 7 S E3-E8
L72 53 S L66,L67,L69,L71
L73 0 S L72 AND ?CROHN?/BIX
L74 0 S L72 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L) (COLON OR COLI
L75 7 S L72 AND ?INTESTIN?/BIX
L76 1 S L72 AND (B14-E10C OR C14-E10C)/MC

L77 1 S L72 AND (B14-E10? OR C14-E10?)/MC
L78 0 S L71 AND A61P001/IPC
L79 1 S L71 AND P73?/M0,M1,M2,M3,M4,M5,M6
L80 1 S L72 AND (B12-J01 OR C12-J01)/MC
L81 8 S L75-L80

FILE 'BIOSIS' ENTERED AT 14:52:19 ON 05 SEP 2004
L82 56 S L8 OR L31

FILE 'HCAPLUS' ENTERED AT 14:52:54 ON 05 SEP 2004
L83 13 S 19 NOR 1 25 () (DIHYDROXYVITAMIN OR DIHYDROXY VITAMIN OR DI HY

FILE 'REGISTRY' ENTERED AT 14:53:32 ON 05 SEP 2004
L84 1 S 131918-61-1
L85 0 S 131918-61-1/CRN

FILE 'HCAPLUS' ENTERED AT 14:53:53 ON 05 SEP 2004
L86 90 S L84
L87 62 S PARICALCITOL OR ZEMPLAR
L88 98 S L83,L86,L87
L89 2 S L88 AND ?CROHN?
L90 2 S L88 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L)COLIT?)
L91 2 S L89,L90
L92 2 S L91 AND L4-L24,L33-L48,L64,L83,L86-L91

FILE 'REGISTRY' ENTERED AT 14:55:50 ON 05 SEP 2004
L93 2 S L84 OR L2

FILE 'REGISTRY' ENTERED AT 14:56:00 ON 05 SEP 2004

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:56:14 ON 05 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2004 VOL 141 ISS 11
FILE LAST UPDATED: 3 Sep 2004 (20040903/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l92 all hitstr tot

L92 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:455025 HCAPLUS
DN 139:30856
ED Entered STN: .13 Jun 2003
TI Treating vitamin D responsive diseases
IN **Hayes, Colleen E.; Nashold, Faye E.**
PA Northern Lights Pharmaceuticals, LLC, USA

SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 469,985.
CODEN: USXXCO

DT Patent

LA English

IC ICM A61K038-20

ICS A61K031-59

NCL 514167000; 424085200

CC 1-12 (Pharmacology)

Section cross-reference(s): 2, 15, 18, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003109506	A1	20030612	US 2002-170746	20020613 <--
	US 6358939	B1	20020319	US 1999-469985	19991221
	WO 2001046132	A1	20010628	WO 2000-US34913	20001221 <--
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	WO 2003106629	A2	20031224	WO 2003-US18558	20030611
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
PRAI	US 1999-469985	A2	19991221		
	WO 2000-US34913	A	20001221	<--	
	US 2002-170746	A	20020613		


CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 2003109506	ICM	A61K038-20
		ICS	A61K031-59
		NCL	514167000; 424085200
	US 2003109506	ECLA	A61K031/59; A61K031/59P <--
AB	The invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biol. active vitamin D compds. in combination with at least one other immunomodulatory compound such as interleukin-10, interleukin-4, or a TNF- α inhibitor.		
ST	vitamin D IL10 immunomodulator antiinflammatory human inflammatory bowel disease; calcitriol cytokine hypercalcemic osteoporosis renal osteodystrophy psoriasis IBD immunomodulator; transdermal patch calcitriol drug screening multiple sclerosis arthritis human; TNFa inhibitor antiinflammatory calcitriol interleukin human inflammatory bowel disease		
IT	Intestine, disease (Crohn's ; treating vitamin D responsive diseases)		
IT	Intestine, disease (inflammatory; treating vitamin D responsive diseases)		
IT	Bone, disease		

- (renal osteodystrophy; treating vitamin D responsive diseases)
- IT Drug delivery systems
(transdermal, controlled-release; treating vitamin D responsive diseases)
- IT Anti-inflammatory agents
Arthritis
Blood serum
Disease, animal
Drug interactions
Drug screening
Feces
Human
Immunomodulators
Multiple sclerosis
Osteoporosis
Psoriasis
(treating vitamin D responsive diseases)
- IT Hemoglobins
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treating vitamin D responsive diseases)
- IT Cytokines
Interleukin 10
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating vitamin D responsive diseases)
- IT Interleukin 4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating vitamin D responsive diseases)
- IT Intestine, disease
(**ulcerative colitis**; treating vitamin D responsive diseases)
- IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia; treating vitamin D responsive diseases)
- IT 50-24-8, Prednisolone 1406-16-2, Vitamin D 32222-06-3, 1,25-Dihydroxyvitamin D3 41294-56-8, 1 α -Hydroxyvitamin D3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating vitamin D responsive diseases)
- IT 103656-37-7 131875-08-6, KH1060 **131918-61-1** 195051-26-4
215714-87-7 233268-76-3, LG 190090 233268-77-4, LG190119
233268-78-5, LG190155 233268-79-6, LG 190176 233268-81-0, LG 190178
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating vitamin D responsive diseases)
- IT **131918-61-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating vitamin D responsive diseases)
- RN 131918-61-1 HCAPLUS
- CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,
(1 α ,3 β ,7E,22E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L92 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:435039 HCAPLUS
 DN 135:41381
 ED Entered STN: 15 Jun 2001
 TI Treatment of **inflammatory bowel** disease with vitamin D compounds
 IN Cantorna, Margherita T.
 PA The Penn State Research Foundation, USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C401-00
 CC 2-10 (Mammalian Hormones)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042205	A2	20010614	WO 2000-US42393	20001130
	WO 2001042205	A3	20020321		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1233942	A2	20020828	EP 2000-992552	20001130
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP	2003516386	T2	20030513	JP 2001-543506	20001130
PRAI	US 1999-168501P	P	19991202		
	US 2000-197827P	P	20000414		
	US 2000-208632P	P	20000601		
	US 2000-231906P	P	20000911		
	WO 2000-US42393	W	20001130		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001042205	ICM	C07C401-00


OS MARPAT 135:41381

AB A method of treating **inflammatory bowel** disease, particularly **ulcerative colitis** and **Crohn's** disease, is disclosed. The method involves administering a vitamin D compound in an amount effective to treat the disease. The administration of a vitamin D compound also prevents the development of or delays the onset of **inflammatory bowel** disease in susceptible individuals.

ST **inflammatory bowel** disease **ulcerative**

- colitis Crohns** vitamin D treatment
- IT Intestine, disease
(**Crohn's**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Intestine, disease
(**inflammatory**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Diet
(low calcium; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Intestine, disease
(**ulcerative colitis**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 1406-16-2, vitamin D
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deficiency; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 32222-06-3D, analogs 41294-56-8, 1 α -Hydroxyvitamin D3 60133-18-8, 1,25-Dihydroxyvitamin D2 75363-22-3 108646-38-4, 1 α ,25-Dihydroxyvitamin D3 triacetate **131918-61-1** 133876-00-3, 1 α -Hydroxyvitamin D 156196-99-5 195051-26-4 217093-03-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT **131918-61-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- RN 131918-61-1 HCAPLUS
- CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 α ,3 β ,7E,22E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=>